ES2683307T3 - Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2 - Google Patents

Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2 Download PDF

Info

Publication number
ES2683307T3
ES2683307T3 ES12767899T ES12767899T ES2683307T3 ES 2683307 T3 ES2683307 T3 ES 2683307T3 ES 12767899 T ES12767899 T ES 12767899T ES 12767899 T ES12767899 T ES 12767899T ES 2683307 T3 ES2683307 T3 ES 2683307T3
Authority
ES
Spain
Prior art keywords
masp
methods
conditions associated
complement activation
treat conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12767899T
Other languages
English (en)
Inventor
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Application granted granted Critical
Publication of ES2683307T3 publication Critical patent/ES2683307T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Un anticuerpo monoclonal contra MASP-2 o un fragmento del mismo que inhibe la activación de la vía de complemento de la lectina dependiente de MASP-2 para su uso en el tratamiento de un sujeto que padece hemoglobinuria paroxística nocturna (HPN), en donde dicho anticuerpo contra MASP-2 o fragmento del mismo se une específicamente a una parte de la SEQ ID NO: 6 e inhibe de manera selectiva la activación de la vía de complemento de la lectina dependiente de MASP-2 mientras que deja intacta la vía de activación de complemento clásica dependiente de C1q.
ES12767899T 2011-04-08 2012-04-06 Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2 Active ES2683307T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473698P 2011-04-08 2011-04-08
PCT/US2012/032650 WO2012139081A2 (en) 2011-04-08 2012-04-06 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (1)

Publication Number Publication Date
ES2683307T3 true ES2683307T3 (es) 2018-09-26

Family

ID=46966283

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17191208T Active ES2894342T3 (es) 2011-04-08 2012-04-06 Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
ES12767899T Active ES2683307T3 (es) 2011-04-08 2012-04-06 Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES17191208T Active ES2894342T3 (es) 2011-04-08 2012-04-06 Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2

Country Status (18)

Country Link
US (5) US8951522B2 (es)
EP (3) EP3964233A1 (es)
JP (4) JP5937197B2 (es)
KR (6) KR101720562B1 (es)
CN (3) CN103781492A (es)
AU (1) AU2012239889B2 (es)
BR (1) BR112013025917A2 (es)
CA (3) CA3076975A1 (es)
CL (1) CL2013002874A1 (es)
DK (2) DK2694108T3 (es)
ES (2) ES2894342T3 (es)
HK (1) HK1250342A1 (es)
IL (3) IL228758B (es)
MX (2) MX339002B (es)
NZ (5) NZ746139A (es)
PL (1) PL3287142T3 (es)
RU (2) RU2743409C2 (es)
WO (1) WO2012139081A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PL3287142T3 (pl) 2011-04-08 2021-12-27 University Of Leicester Sposoby leczenia chorób związanych z aktywacją dopełniacza zależną od masp-2
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
SI2833907T1 (en) * 2012-04-06 2018-07-31 Omeros Corporation COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
LT2914291T (lt) 2012-11-02 2022-06-10 Bioverativ Usa Inc. Antikūnai prieš komplemento c1s ir jų panaudojimo būdai
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ729747A (en) 2013-03-15 2020-03-27 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
EP3057993B1 (en) 2013-10-17 2020-08-12 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
WO2015070041A1 (en) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
CA2949985C (en) 2014-06-12 2023-10-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
IL254670B2 (en) 2015-04-06 2023-04-01 Bioverativ Usa Inc Human anti-c1s antibodies and methods of using them
KR102432062B1 (ko) * 2015-11-09 2022-08-12 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 질병의 치료 방법
KR20180094913A (ko) 2015-12-16 2018-08-24 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
IL305200A (en) 2016-03-31 2023-10-01 Omeros Corp MASP-2 suppressing agents for use in suppressing angiogenesis
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
JP6442703B2 (ja) * 2016-12-26 2018-12-26 日本ビーシージー製造株式会社 細菌細胞壁骨格成分を含有する水中油型エマルション製剤
WO2018164186A1 (ja) * 2017-03-09 2018-09-13 協和発酵キリン株式会社 Ｍａｓｐ２の発現を抑制する核酸
EP3689355A4 (en) * 2017-07-28 2021-09-08 Lemonex Inc. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LIVER CANCER
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3802489A4 (en) * 2018-05-29 2022-04-13 Omeros Corporation MASP -2 INHIBITORS AND METHODS OF USE
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
CN111655849A (zh) 2018-08-21 2020-09-11 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
EP3628735A1 (en) 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
MX2021005758A (es) * 2018-11-15 2021-09-21 Ionis Pharmaceuticals Inc Moduladores de la expresión de irf5.
CN114729354A (zh) * 2018-12-25 2022-07-08 中国医学科学院基础医学研究所 炎性相关疾病防治的小rna药物及其组合
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
US20220162607A1 (en) * 2019-03-14 2022-05-26 Rena Therapeutics Inc. Nucleic acid complex for modulating ihh expression
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
AU2020261059A1 (en) 2019-04-24 2021-10-14 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
JP2022533419A (ja) * 2019-05-22 2022-07-22 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN111024947A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 白色念珠菌荧光免疫层析测定试剂盒及其制备方法
WO2021107057A1 (ja) 2019-11-27 2021-06-03 京セラ株式会社 通信制御方法及びユーザ装置
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
US20210171461A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
IL293588A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
EP4107165A1 (en) * 2020-02-19 2022-12-28 Alnylam Pharmaceuticals, Inc. Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
CN113674860A (zh) * 2020-05-15 2021-11-19 北京大学人民医院 一种难治性iTTP风险预测装置、系统及其应用
AU2022263683A1 (en) * 2021-04-25 2023-11-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
US20240084301A1 (en) * 2022-07-25 2024-03-14 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0640688A1 (en) 1987-12-15 1995-03-01 Gene Shears Pty. Limited Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
WO2000035483A1 (en) 1998-12-15 2000-06-22 The Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
KR20020012320A (ko) 1999-07-21 2002-02-15 그레고리 에이. 데모풀로스 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
CA2391402A1 (en) 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
AU2001279586A1 (en) 2000-07-13 2002-01-30 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
WO2003063799A2 (en) 2002-02-01 2003-08-07 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU2003223288A1 (en) 2002-03-18 2003-10-08 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
AU2003261304A1 (en) 2002-07-30 2004-02-16 Omeros Corporation Ophthalmologic irrigation solutions and method
ITRM20020511A1 (it) * 2002-10-09 2004-04-10 Santa Anna Acuto Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi.
AU2003283217A1 (en) 2002-12-03 2004-06-23 Aarhus Amt Method for determing predisposition to manifestation of immune system related diseases
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2004083250A1 (ja) * 2003-03-17 2004-09-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
EP3530288A3 (en) * 2004-06-10 2019-12-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
ATE544866T1 (de) * 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
WO2007086069A1 (en) 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
RU2477137C2 (ru) 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
AU2010272483B2 (en) 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
CN102958535A (zh) * 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
MX2012010116A (es) 2010-03-01 2013-02-26 Alexion Pharma Inc Metodos y composiciones para el tratamiento de la enfermedad de degos.
PL3287142T3 (pl) 2011-04-08 2021-12-27 University Of Leicester Sposoby leczenia chorób związanych z aktywacją dopełniacza zależną od masp-2
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107011443B (zh) 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
BR112014031522A2 (pt) 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
EP3057993B1 (en) 2013-10-17 2020-08-12 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
KR102432062B1 (ko) 2015-11-09 2022-08-12 오메로스 코포레이션 Masp-2 의존성 보체 활성화와 관련된 질병의 치료 방법
JPWO2018070521A1 (ja) * 2016-10-14 2019-08-15 公立大学法人福島県立医科大学 補体の活性化経路を阻害する融合ポリペプチド

Also Published As

Publication number Publication date
IL228758B (en) 2019-12-31
JP2018024698A (ja) 2018-02-15
CA2832187C (en) 2017-10-10
JP2016185966A (ja) 2016-10-27
JP5937197B2 (ja) 2016-06-22
AU2012239889B2 (en) 2015-09-03
DK3287142T3 (da) 2021-11-01
KR20140009472A (ko) 2014-01-22
RU2018125514A (ru) 2019-03-12
US20120258095A1 (en) 2012-10-11
RU2743409C2 (ru) 2021-02-18
CN103781492A (zh) 2014-05-07
NZ731596A (en) 2022-07-01
JP6584476B2 (ja) 2019-10-02
ES2894342T3 (es) 2022-02-14
CN107638565A (zh) 2018-01-30
PL3287142T3 (pl) 2021-12-27
KR101870915B1 (ko) 2018-06-25
KR20170034941A (ko) 2017-03-29
KR20180072851A (ko) 2018-06-29
EP2694108A4 (en) 2014-10-01
KR102217658B1 (ko) 2021-02-22
EP2694108B1 (en) 2018-06-06
JP6239030B2 (ja) 2017-11-29
IL264172B (en) 2022-04-01
US20220089781A1 (en) 2022-03-24
HK1250342A1 (zh) 2018-12-14
CL2013002874A1 (es) 2014-03-07
JP6893539B2 (ja) 2021-06-23
US8951522B2 (en) 2015-02-10
IL264172A (en) 2019-02-28
WO2012139081A2 (en) 2012-10-11
CN107638565B (zh) 2021-12-21
MX2013011721A (es) 2014-03-05
MX355648B (es) 2018-04-26
EP2694108A2 (en) 2014-02-12
KR20210021101A (ko) 2021-02-24
MX339002B (es) 2016-05-06
BR112013025917A2 (pt) 2016-12-20
CA3076975A1 (en) 2012-10-11
AU2012239889A1 (en) 2013-03-14
US20150239985A1 (en) 2015-08-27
IL228758A0 (en) 2013-12-31
JP2014512363A (ja) 2014-05-22
KR20220044616A (ko) 2022-04-08
US10202465B2 (en) 2019-02-12
NZ709997A (en) 2016-03-31
NZ617298A (en) 2015-08-28
KR101720562B1 (ko) 2017-03-30
EP3287142B1 (en) 2021-08-04
EP3287142A1 (en) 2018-02-28
RU2013149792A (ru) 2015-05-20
NZ746139A (en) 2023-11-24
CA2977009A1 (en) 2012-10-11
CN110075294A (zh) 2019-08-02
US20170166658A1 (en) 2017-06-15
RU2662563C2 (ru) 2018-07-26
CA2832187A1 (en) 2012-10-11
WO2012139081A3 (en) 2012-11-29
US20190292272A1 (en) 2019-09-26
RU2018125514A3 (es) 2019-10-30
DK2694108T3 (en) 2018-08-20
EP3964233A1 (en) 2022-03-09
IL274206A (en) 2020-06-30
CA2977009C (en) 2020-05-05
NZ717517A (en) 2017-07-28
KR20190142445A (ko) 2019-12-26
JP2019214616A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
ES2683307T3 (es) Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
ES2670668T3 (es) Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica
CO7400878A2 (es) Anticuerpos anti-mcam y métodos de uso asociados
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CY1123183T1 (el) Συνθεση για χρηση σε μια μεθοδο θεραπειας υπερβολικου βαρους και παχυσαρκιας σε ασθενεις με υψηλο καρδιαγγειακο κινδυνο
CY1116488T1 (el) Αντισωματα anti-προπερδινης
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EA201791811A1 (ru) Лечение панкреатита
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20161152A1 (es) Anticuerpos y metodos de uso
ES2530428T3 (es) Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EA201101199A1 (ru) Запорный клапан с встроенными опорными элементами
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
CL2013002006A1 (es) Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.
BR112016029008A2 (pt) uso de sulfato de dextrana com peso molecular médio abaixo de 10000 da para induzir a angiogênese em um sujeito
BR112019010671A8 (pt) Composições líquidas que compreendem um agente mucoadesivo
NZ629683A (en) Methods for treating conditions associated with masp-2 dependent complement activation
Cohen et al. Examining Particle Transport in Multi-Spacecraft 3 He-Rich SEP Events
Petersen et al. Characterizing the Effect of Surface Hydrophobicity on Depletion Layer
Carvalho et al. Theoretical study of the Cu PL defect in Si